

FIRST REGULAR SESSION

# SENATE BILL NO. 763

103RD GENERAL ASSEMBLY

INTRODUCED BY SENATOR NICOLA.

2976S.01I

KRISTINA MARTIN, Secretary

## AN ACT

To repeal section 195.017, RSMo, and to enact in lieu thereof two new sections relating to abortifacient drugs, with penalty provisions.

*Be it enacted by the General Assembly of the State of Missouri, as follows:*

Section A. Section 195.017, RSMo, is repealed and two new  
2 sections enacted in lieu thereof, to be known as sections  
3 195.017 and 579.018, to read as follows:

195.017. 1. The department of health and senior  
2 services shall place a substance in Schedule I if it finds  
3 that the substance:

4 (1) Has high potential for abuse; and

5 (2) Has no accepted medical use in treatment in the  
6 United States or lacks accepted safety for use in treatment  
7 under medical supervision.

8 2. Schedule I:

9 (1) The controlled substances listed in this  
10 subsection are included in Schedule I;

11 (2) Any of the following opiates, including their  
12 isomers, esters, ethers, salts, and salts of isomers,  
13 esters, and ethers, unless specifically excepted, whenever  
14 the existence of these isomers, esters, ethers and salts is  
15 possible within the specific chemical designation:

16 (a) Acetyl-alpha-methylfentanyl (N-(1-(1-methyl-2-  
17 phenethyl)-4-piperidiny)-N-phenylacetamide);

18 (b) Acetylmethadol;

**EXPLANATION-Matter enclosed in bold-faced brackets [thus] in this bill is not enacted and is intended to be omitted in the law.**

- 19 (c) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-  
20 phenylacetamide);
- 21 (d) Acryl fentanyl (-(1-phenethylpiperidin-4-yl)-N-  
22 phenylacrylamide);
- 23 (e) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)  
24 cyclohexylmethyl] benzamide);
- 25 (f) Allylprodine;
- 26 (g) Alphacetylmethadol (except levoalphacetylmethadol,  
27 also known as levo-alpha-acetylmethadol levorhodyl acetate  
28 or LAAM);
- 29 (h) Alphameprodine;
- 30 (i) Alphamethadol;
- 31 (j) Alpha-methylfentanyl (N-1-(alphamethyl-beta-  
32 phenyl) ethyl-4-piperidyl) propionanilide; 1-(1-methyl-2-  
33 phenylethyl)-4 ((N-propanilido) piperidine);
- 34 (k) Alpha-methylthiofentanyl (N-(1-methyl-2-(2-  
35 thienyl) ethyl-4-piperidinyl)-N-phenylpropanamide);
- 36 (l) Benzethidine;
- 37 (m) Betacetylmethadol;
- 38 (n) Beta-hydroxyfentanyl (N-(1-(2-hydroxy-2-phenethyl)-  
39 4-piperidinyl)-N-phenylpropanamide);
- 40 (o) Beta-hydroxy-3-methylfentanyl (N-(1-(2-hydroxy-2-  
41 phenethyl)-3-methyl-4-piperidinyl)-N-phenylpropanamide);
- 42 (p) Betameprodine;
- 43 (q) Betamethadol;
- 44 (r) Betaprodine;
- 45 (s) Clonitazene;
- 46 (t) Dextromoramide;
- 47 (u) Diampromide;
- 48 (v) Cyclopropyl fentanyl;
- 49 (w) Diethylthiambutene;
- 50 (x) Difenoxy;

51 (y) Dimenoxadol;  
52 (z) Dimepheptanol;  
53 (aa) Dimethylthiambutene;  
54 (bb) Dioxaphetyl butyrate;  
55 (cc) Dipipanone;  
56 (dd) Ethylmethylthiambutene;  
57 (ee) Etonitazene;  
58 (ff) Etoperidine;  
59 (gg) 4-fluoroisobutyryl fentanyl -(4-fluorophenyl)-N-  
60 (1-phenethylpiperidin-4-yl)isobutyramide;  
61 (hh) Furanyl fentanyl -(1-phenethylpiperidin-4-yl)-N-  
62 phenylfuran-2-carboxamide;  
63 (ii) Furethidine;  
64 (jj) Hydroxypethidine;  
65 (kk) Ketobemidone;  
66 (ll) Levomoramide;  
67 (mm) Levophenacetylmorphan;  
68 (nn) 3-Methylfentanyl (N-(3-methyl-1-(2-phenylethyl)-4-  
69 piperidyl)-N-phenylpropanamide), its optical and geometric  
70 isomers, salts, and salts of isomers;  
71 (oo) 3-Methylthiofentanyl (N-((3-methyl-1-(2-  
72 thienyl)ethyl-4-piperidinyl)-N-phenylpropanamide);  
73 (pp) Methoxyacetyl fentanyl (2-methoxy-N-(1-  
74 phenethylpiperidin-4-yl)-N-phenylacetamide);  
75 (qq) Morpheridine;  
76 (rr) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);  
77 (ss) MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)  
78 piperazine);  
79 (tt) Noracymethadol;  
80 (uu) Norlevorphanol;  
81 (vv) Normethadone;  
82 (ww) Norpipanone;

(xx) Ocfentanil N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetamide;

(yy) Ortho-fluorofentanyl (N-2-(1-phenethylpiperidin-yl)propionamide); other name 2-fluorofentanyl;

(zz) para-fluorobutyryl fentanyl (N-4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide;

(aaa) Para-fluorofentanyl (N-(4-fluorophenyl)-N-(1-(2-phenethyl)-4-piperidinyl) propanamide;

(bbb) PEPAP (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);

(ccc) Phenadoxone;

(ddd) Phenampromide;

(eee) Phenomorphan;

(fff) Phenoperidine;

(ggg) Piritramide;

(hhh) Proheptazine;

(iii) Properidine;

(jjj) Propiram;

(kkk) Racemoramide;

(lll) Tetrahydrofuranyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide);

(mmm) Thiofentanyl (-phenyl-N-(1-(2-thienyl)ethyl-4-piperidinyl)-propanamide;

(nnn) Tilidine;

(ooo) Trimeperidine;

(3) Any of the following opium derivatives, their salts, isomers and salts of isomers unless specifically excepted, whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation:

(a) Acetorphine;

- 115 (b) Acetyldihydrocodeine;
- 116 (c) Benzylmorphine;
- 117 (d) Codeine methylbromide;
- 118 (e) Codeine-N-Oxide;
- 119 (f) Cyprenorphine;
- 120 (g) Desomorphine;
- 121 (h) Dihydromorphine;
- 122 (i) Drotebanol;
- 123 (j) Etorphine (except hydrochloride salt);
- 124 (k) Heroin;
- 125 (l) Hydromorphenol;
- 126 (m) Methyldesorphine;
- 127 (n) Methyldihydromorphine;
- 128 (o) Morphine methylbromide;
- 129 (p) Morphine methylsulfonate;
- 130 (q) Morphine-N-Oxide;
- 131 (r) Myrophine;
- 132 (s) Nicocodeine;
- 133 (t) Nicomorphine;
- 134 (u) Normorphine;
- 135 (v) Pholcodine;
- 136 (w) Thebacon;
- 137 (4) Any of the following opiate similar synthetic
- 138 substances scheduled by the U.S. Drug Enforcement
- 139 Administration as substances that share a pharmacological
- 140 profile similar to fentanyl, morphine, and other synthetic
- 141 opioids, unless specifically excepted or unless listed in
- 142 another schedule:
- 143 (a) Butyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
- 144 phenylbutyramide);
- 145 (b) U-47700 (3,4-Dichloro-N-[2-(dimethylamino)
- 146 cyclohexyl]-methyl benzamide).

(5) Any material, compound, mixture or preparation which contains any quantity of the following hallucinogenic substances, their salts, isomers and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:

- (a) Alpha-ethyltryptamine;
- (b) 4-bromo-2,5-dimethoxyamphetamine;
- (c) 4-bromo-2,5-dimethoxyphenethylamine;
- (d) 2,5-dimethoxyamphetamine;
- (e) 2,5-dimethoxy-4-ethylamphetamine;
- (f) 2,5-dimethoxy-4-(n)-propylthiophenethylamine;
- (g) 2-(2,5-Dimethoxy-4-(n)-propylphenyl) ethanamine;
- (h) 2-(2,5-Dimethoxy-4-ethylphenyl) ethanamine;
- (i) 2-(2,5-Dimethoxy-4-methylphenyl) ethanamine;
- (j) 2-(2,5-Dimethoxy-4-nitro-phenyl) ethanamine;
- (k) 2-(2,5-Dimethoxyphenyl) ethanamine;
- (l) 2-(4-Chloro-2,5-dimethoxyphenyl) ethanamine;
- (m) 2-(4-Ethylthio-2,5-dimethoxyphenyl) ethanamine;
- (n) 2-(4-Iodo-2,5-dimethoxyphenyl) ethanamine;
- (o) 2-(4-Isopropylthio)-2,5-dimethoxyphenyl)  
ethanamine;
- (p) 4-methoxyamphetamine;
- (q) 5-methoxy-3,4-methylenedioxyamphetamine;
- (r) 4-methyl-2, 5-dimethoxyamphetamine;
- (s) 3,4-methylenedioxyamphetamine;
- (t) 3,4-methylenedioxymethamphetamine;
- (u) 3,4-methylenedioxy-N-ethylamphetamine;
- (v) N-hydroxy-3, 4-methylenedioxyamphetamine;
- (w) 3,4,5-trimethoxyamphetamine;
- (x) 5-MeO-DMT or 5-methoxy-N,N-dimethyltryptamine;
- (y) Alpha-methyltryptamine;

- 179 (z) Bufotenine;  
180 (aa) Diethyltryptamine;  
181 (bb) Dimethyltryptamine;  
182 (cc) 5-methoxy-N,N-diisopropyltryptamine;  
183 (dd) Ibogaine;  
184 (ee) Lysergic acid diethylamide;  
185 (ff) Marijuana or marihuana, except industrial hemp;  
186 (gg) Mescaline;  
187 (hh) Parahexyl;  
188 (ii) Peyote, to include all parts of the plant  
189 presently classified botanically as *Lophophora williamsii*  
190 Lemaire, whether growing or not; the seeds thereof; any  
191 extract from any part of such plant; and every compound,  
192 manufacture, salt, derivative, mixture or preparation of the  
193 plant, its seed or extracts;  
194 (jj) N-ethyl-3-piperidyl benzilate;  
195 (kk) N-methyl-3-piperidyl benzilate;  
196 (ll) Psilocybin;  
197 (mm) Psilocyn;  
198 (nn) Tetrahydrocannabinols naturally contained in a  
199 plant of the genus *Cannabis* (cannabis plant), except  
200 industrial hemp, as well as synthetic equivalents of the  
201 substances contained in the cannabis plant, or in the  
202 resinous extractives of such plant, or synthetic substances,  
203 derivatives and their isomers, or both, with similar  
204 chemical structure and pharmacological activity to those  
205 substances contained in the plant, such as the following:  
206 a. 1 cis or trans tetrahydrocannabinol and their  
207 optical isomers;  
208 b. 6 cis or trans tetrahydrocannabinol and their  
209 optical isomers;

210 c. 3,4 cis or trans tetrahydrocannabinol and their  
211 optical isomers;

212 d. Any compounds of these structures, regardless of  
213 numerical designation of atomic positions covered;

214 (oo) Ethylamine analog of phencyclidine;

215 (pp) Pyrrolidine analog of phencyclidine;

216 (qq) Thiophene analog of phencyclidine;

217 (rr) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine;

218 (ss) Salvia divinorum;

219 (tt) Salvinorin A;

220 (uu) Synthetic cannabinoids:

221 a. Any compound structurally derived from 3-(1-  
222 naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane by  
223 substitution at the nitrogen atom of the indole ring by  
224 alkyl, haloalkyl, alkenyl, cycloalkylmethyl,  
225 cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-  
226 morpholinyl)ethyl group, whether or not further substituted  
227 in the indole ring to any extent, whether or not substituted  
228 in the naphthyl ring to any extent. Including, but not  
229 limited to:

230 (i) AM2201, or 1-(5-fluoropentyl)-3-(1-  
231 naphthoyl)indole;

232 (ii) JWH-007, or 1-pentyl-2-methyl-3-(1-  
233 naphthoyl)indole;

234 (iii) JWH-015, or 1-propyl-2-methyl-3-(1-  
235 naphthoyl)indole;

236 (iv) JWH-018, or 1-pentyl-3-(1-naphthoyl)indole;

237 (v) JWH-019, or 1-hexyl-3-(1-naphthoyl)indole;

238 (vi) JWH-073, or 1-butyl-3-(1-naphthoyl)indole;

239 (vii) JWH-081, or 1-pentyl-3-(4-methoxy-1-  
240 naphthoyl)indole;



241 (viii) JWH-098, or 1-pentyl-2-methyl-3-(4-methoxy-1-  
242 naphthoyl)indole;

243 (ix) JWH-122, or 1-pentyl-3-(4-methyl-1-  
244 naphthoyl)indole;

245 (x) JWH-164, or 1-pentyl-3-(7-methoxy-1-  
246 naphthoyl)indole;

247 (xi) JWH-200, or 1-(2-(4-(morpholinyl)ethyl))-3-(1-  
248 naphthoyl)indole;

249 (xii) JWH-210, or 1-pentyl-3-(4-ethyl-1-  
250 naphthoyl)indole;

251 (xiii) JWH-398, or 1-pentyl-3-(4-chloro-1-  
252 naphthoyl)indole;

253 b. Any compound structurally derived from 3-(1-  
254 naphthoyl)pyrrole by substitution at the nitrogen atom of  
255 the pyrrole ring by alkyl, haloalkyl, alkenyl,  
256 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-  
257 piperidiny)methyl or 2-(4-morpholinyl)ethyl group, whether  
258 or not further substituted in the pyrrole ring to any  
259 extent, whether or not substituted in the naphthyl ring to  
260 any extent;

261 c. Any compound structurally derived from 1-(1-  
262 naphthylmethyl)indene by substitution at the 3-position of  
263 the indene ring by alkyl, haloalkyl, alkenyl,  
264 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-  
265 piperidiny)methyl or 2-(4-morpholinyl)ethyl group, whether  
266 or not further substituted in the indene ring to any extent,  
267 whether or not substituted in the naphthyl ring to any  
268 extent;

269 d. Any compound structurally derived from 3-  
270 phenylacetylindole by substitution at the nitrogen atom of  
271 the indole ring with alkyl, haloalkyl, alkenyl,  
272 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-

piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent, whether or not substituted in the phenyl ring to any extent. Including, but not limited to:

(i) JWH-201, or 1-pentyl-3-(4-methoxyphenylacetyl)indole;

(ii) JWH-203, or 1-pentyl-3-(2-chlorophenylacetyl)indole;

(iii) JWH-250, or 1-pentyl-3-(2-methoxyphenylacetyl)indole;

(iv) JWH-251, or 1-pentyl-3-(2-methylphenylacetyl)indole;

(v) RCS-8, or 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole;

e. Any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of the phenolic ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not substituted in the cyclohexyl ring to any extent. Including, but not limited to CP 47, 497 and homologues, or 2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol, where side chain n=5, and homologues where side chain n=4, 6, or 7;

f. Any compound containing a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent. Including, but not limited to:

- 305 (i) AM-694, or 1-(5-fluoropentyl)-3-(2-  
306 iodobenzoyl)indole;
- 307 (ii) RCS-4, or 1-pentyl-3-(4-methoxybenzoyl)indole (SR-  
308 19 and RCS-4);
- 309 g. CP 50,556-1, or [(6S,6aR,9R,10aR)-9-hydroxy-6-  
310 methyl-3-[(2R)-5-phenylpentan-2-yl] oxy-5,6,6a,7,8,9,10,10a-  
311 octahydrophenanthridin-1-yl] acetate;
- 312 h. HU-210, or (6aR,10aR)-9-(hydroxymethyl)-6,6-  
313 dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-  
314 tetrahydrobenzo[c]chromen-1-ol;
- 315 i. HU-211, or Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-  
316 6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-  
317 tetrahydrobenzo[c]chromen-1-ol;
- 318 j. Dimethylheptylpyran, or DMHP;
- 319 (6) Any material, compound, mixture or preparation  
320 containing any quantity of the following substances having a  
321 depressant effect on the central nervous system, including  
322 their salts, isomers and salts of isomers whenever the  
323 existence of these salts, isomers and salts of isomers is  
324 possible within the specific chemical designation:
- 325 (a) Gamma-hydroxybutyric acid;
- 326 (b) Mecloqualone;
- 327 (c) Methaqualone;
- 328 (7) Any material, compound, mixture or preparation  
329 containing any quantity of the following substances having a  
330 stimulant effect on the central nervous system, including  
331 their salts, isomers and salts of isomers:
- 332 (a) Aminorex;
- 333 (b) N-benzylpiperazine;
- 334 (c) Cathinone;
- 335 (d) Fenethylline;
- 336 (e) 3-Fluoromethcathinone;

- 337 (f) 4-Fluoromethcathinone;
- 338 (g) Mephedrone, or 4-methylmethcathinone;
- 339 (h) Methcathinone;
- 340 (i) 4-methoxymethcathinone;
- 341 (j) (+,-)cis-4-methylaminorex ((+,-)cis-4,5-dihydro-4-
- 342 methyl-5-phenyl-2-oxazamine);
- 343 (k) Methylenedioxypropylone, MDPV, or 1-(1,3-
- 344 Benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-pentanone;
- 345 (l) Methylenedioxypropylmethcathinone;
- 346 (m) 4-Methyl-alpha-pyrrolidinobutylphenone, or MPBP;
- 347 (n) N-ethylamphetamine;
- 348 (o) N,N-dimethylamphetamine;
- 349 (p) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-
- 350 22; QUPIC);
- 351 (q) Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-
- 352 carboxylate (5-fluoro-PB-22; 5F-PB-22);
- 353 (r) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-
- 354 fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA);
- 355 (s) N-(1-amino-3, 3-dimethyl-1-oxobutan-2-yl)-1-pentyl-
- 356 1H-indazole-3-carboxamide (ADB-PINACA);
- 357 (8) A temporary listing of substances subject to
- 358 emergency scheduling under federal law shall include any
- 359 material, compound, mixture or preparation which contains
- 360 any quantity of the following substances:
- 361 (a) (1-pentyl-1H-indol-3-yl)(2,2,3,3-
- 362 tetramethylcyclopropyl)methanone, its optical, positional,
- 363 and geometric isomers, salts, and salts of isomers;
- 364 (b) [1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-
- 365 tetramethylcyclopropyl)methanone, its optical, positional,
- 366 and geometric isomers, salts, and salts of isomers;

367 (c) N-(1-adamantyl)-1-pentyl-1H-indazole-3-  
368 carboxamide, its optical, positional, and geometric isomers,  
369 salts, and salts of isomers;

370 (d) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-  
371 methoxybenzyl)ethanamine, its optical, positional, and  
372 geometric isomers, salts, and salts of isomers;

373 (e) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-  
374 methoxybenzyl)ethanamine, its optical, positional, and  
375 geometric isomers, salts, and salts of isomers;

376 (f) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-  
377 methoxybenzyl)ethanamine, its optical, positional, and  
378 geometric isomers, salts, and salts of isomers;

379 (g) 4-methyl-N-ethylcathinone, its optical,  
380 positional, and geometric isomers, salts, and salts of  
381 isomers;

382 (h) 4-methyl-alpha-pyrrolidinopropiophenone, its  
383 optical, positional, and geometric isomers, salts, and salts  
384 of isomers;

385 (i) Alpha-pyrrolidinopentiophenone, its optical,  
386 positional, and geometric isomers, salts, and salts of  
387 isomers;

388 (j) Butylone, its optical, positional, and geometric  
389 isomers, salts, and salts of isomers;

390 (k) Pentedrone, its optical, positional, and geometric  
391 isomers, salts, and salts of isomers;

392 (l) Pentylone, its optical, positional, and geometric  
393 isomers, salts, and salts of isomers;

394 (m) Naphyrone, its optical, positional, and geometric  
395 isomers, salts, and salts of isomers;

396 (n) Alpha-pyrrolidinobutiophenone, its optical,  
397 positional, and geometric isomers, salts, and salts of  
398 isomers;

- 399 (o) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-  
400 (cyclohexylmethyl)-1H-indazole-3-carboxamide, its optical,  
401 positional, and geometric isomers, salts, and salts of  
402 isomers;
- 403 (p) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-  
404 indazole-3-carboxamide, its optical, positional, and  
405 geometric isomers, salts, and salts of isomers;
- 406 (q) [1-(5-fluoropentyl)-1H-indazole-3-yl](naphthalen-1-  
407 yl)methanone, its optical, positional, and geometric  
408 isomers, salts, and salts of isomers;
- 409 (r) N-[1-[2-hydroxy-2-(thiophen-2-yl) ethyl]piperidin-  
410 4-yl]-N-phenylpropionamide, its isomers, esters, ethers,  
411 salts, and salts of isomers, esters, and ethers;
- 412 (s) N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide,  
413 its optical, positional, and geometric isomers, salts, and  
414 salts of isomers;
- 415 (t) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-  
416 (cyclohexylmethyl)-1H-indazole-3-carboxamide, its optical,  
417 positional, and geometric isomers, salts, and salts of  
418 isomers;
- 419 (u) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-  
420 carboxamido)-3,3-dimethylbutanoate, its optical, positional,  
421 and geometric isomers, salts, and salts of isomers;
- 422 (v) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-  
423 carboxamido)-3-methylbutanoate, its optical, positional, and  
424 geometric isomers, salts, and salts of isomers;
- 425 (w) N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-  
426 3-carboxamide, its optical, positional, and geometric  
427 isomers, salts, and salts of isomers;
- 428 (x) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-  
429 fluorobenzyl)-1H-indazole-3-carboxamide, its optical,

430 positional, and geometric isomers, salts, and salts of  
431 isomers;

432 (y) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-  
433 carboxamido)-3,3-dimethylbutanoate, its optical, positional,  
434 and geometric isomers, salts, and salts of isomers;

435 (z) methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-  
436 carboxamido)-3,3-dimethylbutanoate, its optical, positional,  
437 and geometric isomers, salts, and salts of isomers;

438 (aa) N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-  
439 yl)propionamide, its isomers, esters, ethers, salts, and  
440 salts of isomers, esters, and ethers;

441 (bb) methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-  
442 carboxamido)-3-methylbutanoate, its optical, positional, and  
443 geometric isomers, salts, and salts of isomers;

444 (cc) N-(1-phenethylpiperidin-4-yl)-N-  
445 phenylcyclopropanecarboxamide, its isomers, esters, ethers,  
446 salts, and salts of isomers, esters, and ethers;

447 (dd) N-(1-phenethylpiperidin-4-yl)-N-  
448 phenylpentanamide, its isomers, esters, ethers, salts, and  
449 salts of isomers, esters, and ethers;

450 (ee) N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-  
451 yl)butyramide, its isomers, esters, ethers, salts, and salts  
452 of isomers, esters, and ethers;

453 (ff) N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-  
454 yl)butyramide, its isomers, esters, ethers, salts, and salts  
455 of isomers, esters, and ethers;

456 (gg) N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-  
457 yl)isobutyramide, its isomers, esters, ethers, salts, and  
458 salts of isomers, esters, and ethers;

459 (hh) N-(1-phenethylpiperidin-4-yl)-N-  
460 phenylisobutyramide, its isomers, esters, ethers, salts, and  
461 salts of isomers, esters, and ethers;

462 (ii) N-(1-phenethylpiperidin-4-yl)-N-  
463 phenylcyclopentanecarboxamide, its isomers, esters, ethers,  
464 salts, and salts of isomers, esters, and ethers;

465 (jj) Fentanyl-related substances, their isomers,  
466 esters, ethers, salts, and salts of isomers, esters, and  
467 ethers. Fentanyl-related substance shall mean any substance  
468 not otherwise listed under another Drug Enforcement  
469 Administration Controlled Substance Code Number, and for  
470 which no exemption or approval is in effect under section  
471 505 of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C.  
472 Section 355, that is structurally related to fentanyl by one  
473 or more of the following modifications:

474 a. Replacement of the phenyl portion of the phenethyl  
475 group by any monocycle, whether or not further substituted  
476 in or on the monocycle;

477 b. Substitution in or on the phenethyl group with  
478 alkyl, alkenyl, alkoxyl, hydroxyl, halo, haloalkyl, amino or  
479 nitro groups;

480 c. Substitution in or on the piperidine ring with  
481 alkyl, alkenyl, alkoxyl, ester, ether, hydroxyl, amino or  
482 nitro groups;

483 d. Replacement of the aniline ring with any aromatic  
484 monocycle, whether or not further substituted in or on the  
485 aromatic monocycle; or

486 e. Replacement of the N-propionyl group by another  
487 acyl group;

488 (kk) Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-  
489 carboxylate, its optical, positional, and geometric isomers,  
490 salts, and salts of isomers (NM2201; CBL2201);

491 (ll) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-  
492 fluoropentyl)-1H-indazole-3-carboxamide, its optical,



493 positional, and geometric isomers, salts, and salts of  
494 isomers (5F-AB-PINACA);  
495 (mm) 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-  
496 indazole-3-carboxamide, its optical, positional, and  
497 geometric isomers, salts, and salts of isomers (4-CN-CUMYL-  
498 BUTINACA; 4-cyano-CUMYL-BUTINACA; 4-CN-CUMYLBINACA; CUMYL-  
499 4CN-BINACA; SGT-78);  
500 (nn) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-  
501 carboxamido)-3-methylbutanoate, its optical, positional, and  
502 geometric isomers, salts, and salts of isomers (MMB-CHMICA,  
503 AMB-CHMICA);  
504 (oo) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-  
505 pyrrolo[2,3-b]pyridine-3-carboxamide, its optical,  
506 positional, and geometric isomers, salts, and salts of  
507 isomers (5F-CUMYL-P7AICA);  
508 (pp) N-ethylpentylone, its optical, positional, and  
509 geometric isomers, salts, and salts of isomers (ephylone, 1-  
510 (1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one;  
511 (qq) ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-  
512 carboxamido)-3,3-dimethylbutanoate, its optical, positional,  
513 and geometric isomers, salts, and salts of isomers (trivial  
514 name: 5F-EDMB-PINACA);  
515 (rr) methyl 2-(1-(5-fluoropentyl)-1H-indole-3-  
516 carboxamido)-3,3-dimethylbutanoate, its optical, positional,  
517 and geometric isomers, salts, and salts of isomers (trivial  
518 name: 5F-MDMB-PICA);  
519 (ss) N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-  
520 3-carboxamide, its optical, positional, and geometric  
521 isomers, salts, and salts of isomers (trivial names: FUB-  
522 AKB48; FUB-APINACA; AKB48 N-(4-FLUOROBENZYL));  
523 (tt) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-  
524 indazole-3-carboxamide, its optical, positional, and

525 geometric isomers, salts, and salts of isomers (trivial  
526 names: 5F-CUMYL-PINACA; SGT-25);

527 (uu) (1-(4-fluorobenzyl)-1H-indol-3-yl) (2,2,3,3-  
528 tetramethylcyclopropyl) methanone, its optical, positional,  
529 and geometric isomers, salts, and salts of isomers (trivial  
530 name: FUB-144);

531 (vv) N-ethylhexedrone, its optical, positional, and  
532 geometric isomers, salts, and salts of isomers (Other name:  
533 2-(ethylamino)-1-phenylhexan-1-one);

534 (ww) alpha-pyrrolidinohexanophenone, its optical,  
535 positional, and geometric isomers, salts, and salts of  
536 isomers (Other names:  $\alpha$ -PHP; alpha-pyrrolidinohexiophenone;  
537 1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one);

538 (xx) 4-methyl-alpha-ethylaminopentiophenone, its  
539 optical, positional, and geometric isomers, salts, and salts  
540 of isomers; (Other names: 4-MEAP; 2-(ethylamino)-1-(4-  
541 methylphenyl)pentan-1-one);

542 (yy) 4'-methyl-alpha-pyrrolidinohexiophenone, its  
543 optical, positional, and geometric isomers, salts, and salts  
544 of isomers (Other names: MPHP; 4'-methyl-alpha-  
545 pyrrolidinohexanophenone; 1-(4-methylphenyl)-2-(pyrrolidin-1-  
546 yl)hexan-1-one);

547 (zz) alpha-pyrrolidinoheptaphenone, its optical,  
548 positional, and geometric isomers, salts, and salts of  
549 isomers (Other names: PV8; 1-phenyl-2-(pyrrolidin-1-  
550 yl)heptan-1-one);

551 (aaa) 4'-chloro-alpha-pyrrolidinovalerophenone, its  
552 optical, positional, and geometric isomers, salts, and salts  
553 of isomers (Other names: 4-chloro- $\alpha$ -PVP; 4'-chloro-alpha-  
554 pyrrolidinopentiophenone; 1-(4-chlorophenyl)-2-(pyrrolidin-1-  
555 yl)pentan-1-one);

(9) Khat, to include all parts of the plant presently classified botanically as *catha edulis*, whether growing or not; the seeds thereof; any extract from any part of such plant; and every compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seed or extracts.

3. The department of health and senior services shall place a substance in Schedule II if it finds that:

(1) The substance has high potential for abuse;

(2) The substance has currently accepted medical use in treatment in the United States, or currently accepted medical use with severe restrictions; and

(3) The abuse of the substance may lead to severe psychic or physical dependence.

4. The controlled substances listed in this subsection are included in Schedule II:

(1) Any of the following substances whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by combination of extraction and chemical synthesis:

(a) Opium and opiate; and any salt, compound, derivative or preparation of opium or opiate, excluding apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmeffene, naloxegol, naloxone, and naltrexone, and their respective salts, but including the following:

- a. Raw opium;
- b. Opium extracts;
- c. Opium fluid;
- d. Powdered opium;
- e. Granulated opium;
- f. Tincture of opium;
- g. Codeine;

- 588 h. Dihydroetorphine;
- 589 i. Ethylmorphine;
- 590 j. Etorphine hydrochloride;
- 591 k. Hydrocodone;
- 592 l. Hydromorphone;
- 593 m. Metopon;
- 594 n. Morphine;
- 595 o. Oripavine;
- 596 p. Oxycodone;
- 597 q. Oxymorphone;
- 598 r. Thebaine;

599 (b) Any salt, compound, derivative, or preparation  
600 thereof which is chemically equivalent or identical with any  
601 of the substances referred to in this subdivision, but not  
602 including the isoquinoline alkaloids of opium;

603 (c) Opium poppy and poppy straw;

604 (d) Coca leaves and any salt, compound, derivative, or  
605 preparation of coca leaves, and any salt, compound,  
606 derivative, or preparation thereof which is chemically  
607 equivalent or identical with any of these substances, but  
608 not including the following:

609 a. Decocainized coca leaves or extractions of coca  
610 leaves, which extractions do not contain cocaine or  
611 ecgonine; or

612 b. Ioflupane;

613 (e) Concentrate of poppy straw (the crude extract of  
614 poppy straw in either liquid, solid or powder form which  
615 contains the phenanthrene alkaloids of the opium poppy);

616 (2) Any of the following opiates, including their  
617 isomers, esters, ethers, salts, and salts of isomers,  
618 whenever the existence of these isomers, esters, ethers, and

619 salts is possible within the specific chemical designation,  
620 dextrophan and levopropoxyphene excepted:

- 621 (a) Alfentanil;
- 622 (b) Alphaprodine;
- 623 (c) Anileridine;
- 624 (d) Bezitramide;
- 625 (e) Bulk dextropropoxyphene;
- 626 (f) Carfentanil;
- 627 (g) Dihydrocodeine;
- 628 (h) Diphenoxylate;
- 629 (i) Fentanyl;
- 630 (j) Isomethadone;
- 631 (k) Levo-alphaacetylmethadol;
- 632 (l) Levomethorphan;
- 633 (m) Levorphanol;
- 634 (n) Metazocine;
- 635 (o) Methadone;
- 636 (p) Methadone-Intermediate, 4-cyano-2-dimethylamino-4,  
637 4-diphenylbutane;
- 638 (q) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-  
639 diphenylpropane-carboxylic acid;
- 640 (r) Pethidine (meperidine);
- 641 (s) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-  
642 phenylpiperidine;
- 643 (t) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-  
644 4-carboxylate;
- 645 (u) Pethidine-Intermediate-C, 1-methyl-4-  
646 phenylpiperidine-4-carboxylic acid;
- 647 (v) Phenazocine;
- 648 (w) Piminodine;
- 649 (x) Racemethorphan;
- 650 (y) Racemorphan;

651 (z) Remifentanil;  
652 (aa) Sufentanil;  
653 (bb) Tapentadol;  
654 (cc) Thiafentanil;  
655 (3) Any material, compound, mixture, or preparation  
656 which contains any quantity of the following substances  
657 having a stimulant effect on the central nervous system:  
658 (a) Amphetamine, its salts, optical isomers, and salts  
659 of its optical isomers;  
660 (b) Lisdexamfetamine, its salts, isomers, and salts of  
661 its isomers;  
662 (c) Methamphetamine, its salts, isomers, and salts of  
663 its isomers;  
664 (d) Phenmetrazine and its salts;  
665 (e) Methylphenidate;  
666 (4) Any material, compound, mixture, or preparation  
667 which contains any quantity of the following substances  
668 having a depressant effect on the central nervous system,  
669 including its salts, isomers, and salts of isomers whenever  
670 the existence of those salts, isomers, and salts of isomers  
671 is possible within the specific chemical designation:  
672 (a) Amobarbital;  
673 (b) Glutethimide;  
674 (c) Pentobarbital;  
675 (d) Phencyclidine;  
676 (e) Secobarbital;  
677 (5) Hallucinogenic substances:  
678 (a) Any material or compound which contains any  
679 quantity of nabilone;  
680 (b) Dronabinol [(-)- $\Delta$ -9-trans tetrahydrocannabinol] in  
681 an oral solution in a drug product approved for marketing by  
682 the U.S. Food and Drug Administration;

(6) Any material, compound, mixture, or preparation which contains any quantity of the following substances:

(a) Immediate precursor to amphetamine and methamphetamine: Phenylacetone;

(b) Immediate precursors to phencyclidine (PCP):

a. 1-phenylcyclohexylamine;

b. 1-piperidinocyclohexanecarbonitrile (PCC);

(c) Immediate precursor to fentanyl: 4-anilino-N-phenethyl-4-piperidine (ANPP);

(7) Any material, compound, mixture, or preparation which contains any quantity of the following alkyl nitrites:

(a) Amyl nitrite;

(b) Butyl nitrite.

5. The department of health and senior services shall place a substance in Schedule III if it finds that:

(1) The substance has a potential for abuse less than the substances listed in Schedules I and II;

(2) The substance has currently accepted medical use in treatment in the United States; and

(3) Abuse of the substance may lead to moderate or low physical dependence or high psychological dependence.

6. The controlled substances listed in this subsection are included in Schedule III:

(1) Any material, compound, mixture, or preparation which contains any quantity of the following substances having a potential for abuse associated with a stimulant effect on the central nervous system:

(a) Benzphetamine;

(b) Chlorphentermine;

(c) Clortermine;

(d) Phendimetrazine;

714           (2) Any material, compound, mixture or preparation  
715 which contains any quantity or salt of the following  
716 substances or salts having a depressant effect on the  
717 central nervous system:

718           (a) Any material, compound, mixture or preparation  
719 which contains any quantity or salt of the following  
720 substances combined with one or more active medicinal  
721 ingredients:

- 722           a. Amobarbital;
- 723           b. Secobarbital;
- 724           c. Pentobarbital;

725           (b) Any suppository dosage form containing any  
726 quantity or salt of the following:

- 727           a. Amobarbital;
- 728           b. Secobarbital;
- 729           c. Pentobarbital;

730           (c) Any substance which contains any quantity of a  
731 derivative of barbituric acid or its salt;

- 732           (d) Chlorhexadol;
- 733           (e) Embutramide;

734           (f) Gamma hydroxybutyric acid and its salts, isomers,  
735 and salts of isomers contained in a drug product for which  
736 an application has been approved under Section 505 of the  
737 federal Food, Drug, and Cosmetic Act;

738           (g) Ketamine, its salts, isomers, and salts of isomers;

739           (h) Lysergic acid;

740           (i) Lysergic acid amide;

741           (j) Methyprylon;

742           (k) Perampanel, and its salts, isomers, and salts of  
743 isomers;

744           (l) Sulfondiethylmethane;

745           (m) Sulfonethylmethane;



746           (n)    Sulfonmethane;  
747           (o)    Tiletamine and zolazepam or any salt thereof;  
748           (3)    Nalorphine;  
749           (4)    Any material, compound, mixture, or preparation  
750 containing limited quantities of any of the following  
751 narcotic drugs or their salts:  
752           (a)    Not more than 1.8 grams of codeine per one hundred  
753 milliliters or not more than ninety milligrams per dosage  
754 unit, with an equal or greater quantity of an isoquinoline  
755 alkaloid of opium;  
756           (b)    Not more than 1.8 grams of codeine per one hundred  
757 milliliters or not more than ninety milligrams per dosage  
758 unit with one or more active, nonnarcotic ingredients in  
759 recognized therapeutic amounts;  
760           (c)    Not more than 1.8 grams of dihydrocodeine per one  
761 hundred milliliters or not more than ninety milligrams per  
762 dosage unit, with one or more active, nonnarcotic  
763 ingredients in recognized therapeutic amounts;  
764           (d)    Not more than three hundred milligrams of  
765 ethylmorphine per one hundred milliliters or not more than  
766 fifteen milligrams per dosage unit, with one or more active,  
767 nonnarcotic ingredients in recognized therapeutic amounts;  
768           (e)    Not more than five hundred milligrams of opium per  
769 one hundred milliliters or per one hundred grams or not more  
770 than twenty-five milligrams per dosage unit, with one or  
771 more active nonnarcotic ingredients in recognized  
772 therapeutic amounts;  
773           (f)    Not more than fifty milligrams of morphine per one  
774 hundred milliliters or per one hundred grams, with one or  
775 more active, nonnarcotic ingredients in recognized  
776 therapeutic amounts;

777 (5) Any material, compound, mixture, or preparation  
778 containing any of the following narcotic drugs or their  
779 salts: Buprenorphine;

780 (6) Anabolic steroids. Any drug or hormonal  
781 substance, chemically and pharmacologically related to  
782 testosterone (other than estrogens, progestins,  
783 corticosteroids, and dehydroepiandrosterone) that promotes  
784 muscle growth, except an anabolic steroid which is expressly  
785 intended for administration through implants to cattle or  
786 other nonhuman species and which has been approved by the  
787 Secretary of Health and Human Services for that  
788 administration. If any person prescribes, dispenses, or  
789 distributes such steroid for human use, such person shall be  
790 considered to have prescribed, dispensed, or distributed an  
791 anabolic steroid within the meaning of this subdivision.  
792 Unless specifically excepted or unless listed in another  
793 schedule, any material, compound, mixture or preparation  
794 containing any quantity of the following substances,  
795 including its salts, esters and ethers:

- 796 (a)  $3\beta,17\beta$ -dihydroxy- $5\alpha$ -androstane;  
797 (b)  $3\alpha,17\beta$ -dihydroxy- $5\alpha$ -androstane;  
798 (c)  $5\alpha$ -androstane-3,17-dione;  
799 (d) 1-androstenediol ( $3\beta,17\beta$ -dihydroxy- $5\alpha$ -androst-1-  
800 ene);  
801 (e) 1-androstenediol ( $3\alpha,17\beta$ -dihydroxy- $5\alpha$ -androst-1-  
802 ene);  
803 (f) 4-androstenediol ( $3\beta,17\beta$ -dihydroxy-androst-4-ene);  
804 (g) 5-androstenediol ( $3\beta,17\beta$ -dihydroxy-androst-5-ene);  
805 (h) 1-androstenedione ([ $5\alpha$ ]-androst-1-en-3,17-dione);  
806 (i) 4-androstenedione (androst-4-en-3,17-dione);  
807 (j) 5-androstenedione (androst-5-en-3,17-dione);

808 (k) Bolasterone ( $7\alpha$ ,  $17\alpha$ -dimethyl- $17\beta$ -hydroxyandrost-4-  
809 en-3-one);  
810 (l) Boldenone ( $17\beta$ -hydroxyandrost-1,4,-diene-3-one);  
811 (m) Boldione;  
812 (n) Calusterone ( $7\beta$ ,  $17\alpha$ -dimethyl- $17\beta$ -hydroxyandrost-4-  
813 en-3-one);  
814 (o) Clostebol (4-chloro- $17\beta$ -hydroxyandrost-4-en-3-one);  
815 (p) Dehydrochloromethyltestosterone (4-chloro- $17\beta$ -  
816 hydroxy- $17\alpha$ -methyl-androst-1,4-dien-3-one);  
817 (q) Desoxymethyltestosterone;  
818 (r) 4-dihydrotestosterone ( $17\beta$ -hydroxy-androstan-3-  
819 one);  
820 (s) Drostanolone ( $17\beta$ -hydroxy- $2\alpha$ -methyl- $5\alpha$ -androstan-3-  
821 one);  
822 (t) Ethylestrenol ( $17\alpha$ -ethyl- $17\beta$ -hydroxyestr-4-ene);  
823 (u) Fluoxymesterone (9-fluoro- $17\alpha$ -methyl- $11\beta$ ,  $17\beta$ -  
824 dihydroxyandrost-4-en-3-one);  
825 (v) Formebolone (2-formyl- $17\alpha$ -methyl- $11\alpha$ ,  $17\beta$ -  
826 dihydroxyandrost-1,4-dien-3-one);  
827 (w) Furazabol ( $17\alpha$ -methyl- $17\beta$ -hydroxyandrostano[2,3-c]-  
828 furazan);  
829 (x)  $13\beta$ -ethyl- $17\beta$ -hydroxygon-4-en-3-one;  
830 (y) 4-hydroxytestosterone (4,  $17\beta$ -dihydroxy-androst-4-  
831 en-3-one);  
832 (z) 4-hydroxy-19-nortestosterone (4,  $17\beta$ -dihydroxy-estr-  
833 4-en-3-one);  
834 (aa) Mestanolone ( $17\alpha$ -methyl- $17\beta$ -hydroxy- $5\alpha$ -androstan-  
835 3-one);  
836 (bb) Mesterolone ( $1\alpha$ - methyl- $17\beta$ -hydroxy-[ $5\alpha$ ]-  
837 androstan-3-one);  
838 (cc) Methandienone ( $17\alpha$ -methyl- $17\beta$ -hydroxyandrost-1,4-  
839 dien-3-one);

840 (dd) Methandriol ( $17\alpha$ -methyl- $3\beta$ , $17\beta$ -dihydroxyandrost-5-  
841 ene);  
842 (ee) Methasterone ( $2\alpha$ , $17\alpha$ -dimethyl- $5\alpha$ -androstan- $17\beta$ -ol-  
843 3-one);  
844 (ff) Methenolone (1-methyl- $17\beta$ -hydroxy- $5\alpha$ -androst-1-en-  
845 3-one);  
846 (gg)  $17\alpha$ -methyl- $3\beta$ , $17\beta$ -dihydroxy- $5\alpha$ -androstan-3-one;  
847 (hh)  $17\alpha$ -methyl- $3\alpha$ , $17\beta$ -dihydroxy- $5\alpha$ -androstan-3-one;  
848 (ii)  $17\alpha$ -methyl- $3\beta$ , $17\beta$ -dihydroxyandrost-4-ene;  
849 (jj)  $17\alpha$ -methyl-4-hydroxynandrolone ( $17\alpha$ -methyl-4-  
850 hydroxy- $17\beta$ -hydroxyestr-4-en-3-one);  
851 (kk) Methyldienolone ( $17\alpha$ -methyl- $17\beta$ -hydroxyestra-  
852 4,9(10)-dien-3-one);  
853 (ll) Methyltrienolone ( $17\alpha$ -methyl- $17\beta$ -hydroxyestra-  
854 4,9,11-trien-3-one);  
855 (mm) Methyltestosterone ( $17\alpha$ -methyl- $17\beta$ -hydroxyandrost-  
856 4-en-3-one);  
857 (nn) Mibolerone ( $7\alpha$ , $17\alpha$ -dimethyl- $17\beta$ -hydroxyestr-4-en-  
858 3-one);  
859 (oo)  $17\alpha$ -methyl- $\Delta^1$ -dihydrotestosterone ( $17\beta$ -hydroxy-  
860  $17\alpha$ -methyl- $5\alpha$ -androst-1-en-3-one) (a.k.a. '17- $\alpha$ -methyl-1-  
861 testosterone');  
862 (pp) Nandrolone ( $17\beta$ -hydroxyestr-4-ene-3-one);  
863 (qq) 19-nor-4-androstenediol ( $3\beta$ , $17\beta$ -dihydroxyestr-4-  
864 ene);  
865 (rr) 19-nor-4-androstenediol ( $3\alpha$ , $17\beta$ -dihydroxyestr-4-  
866 ene);  
867 (ss) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-  
868 diene-3,17-dione);  
869 (tt) 19-nor-5-androstenediol ( $3\beta$ , $17\beta$ -dihydroxyestr-5-  
870 ene);

871 (uu) 19-nor-5-androstenediol ( $3\alpha, 17\beta$ -dihydroxyestr-5-  
872 ene);  
873 (vv) 19-nor-4-androstenedione (estr-4-en-3,17-dione);  
874 (ww) 19-nor-5-androstenedione (estr-5-en-3,17-dione);  
875 (xx) Norbolethone ( $13\beta, 17\alpha$ -diethyl- $17\beta$ -hydroxygon-4-en-  
876 3-one);  
877 (yy) Norclostebol (4-chloro- $17\beta$ -hydroxyestr-4-en-3-  
878 one);  
879 (zz) Norethandrolone ( $17\alpha$ -ethyl- $17\beta$ -hydroxyestr-4-en-3-  
880 one);  
881 (aaa) Normethandrolone ( $17\alpha$ -methyl- $17\beta$ -hydroxyestr-4-  
882 en-3-one);  
883 (bbb) Oxandrolone ( $17\alpha$ -methyl- $17\beta$ -hydroxy-2-oxa-[ $5\alpha$ ]-  
884 androstan-3-one);  
885 (ccc) Oxymesterone ( $17\alpha$ -methyl-4, $17\beta$ -dihydroxyandrost-  
886 4-en-3-one);  
887 (ddd) metholone ( $17\alpha$ -methyl-2-hydroxymethylene- $17\beta$ -  
888 hydroxy-[ $5\alpha$ ]-androstan-3-one);  
889 (eee) Prostanazol ( $17\beta$ -hydroxy- $5\alpha$ -androstan[3,2-  
890 c]pyrazole);  
891 (fff) Stanolone ( $\Delta 1$ -dihydrotestosterone (a.k.a. 1-  
892 testosterone) ( $17\beta$ -hydroxy- $5\alpha$ -androst-1-en-3-one));  
893 (ggg) Stanozolol ( $17\alpha$ -methyl- $17\beta$ -hydroxy-[ $5\alpha$ ]-androst-  
894 2-eno[3,2-c]-pyrazole);  
895 (hhh) Stenbolone ( $17\beta$ -hydroxy-2-methyl-[ $5\alpha$ ]-androst-1-  
896 en-3-one);  
897 (iii) Testolactone (13-hydroxy-3-oxo-13,17-  
898 secoandrosta-1,4-dien-17-oic acid lactone);  
899 (jjj) Testosterone ( $17\beta$ -hydroxyandrost-4-en-3-one);  
900 (kkk) Tetrahydrogestrinone ( $13\beta, 17\alpha$ -diethyl- $17\beta$ -  
901 hydroxygon-4,9,11-trien-3-one);  
902 (lll) Trenbolone ( $17\beta$ -hydroxyestr-4,9,11-trien-3-one);

903           (mmm) Any salt, ester, or ether of a drug or substance  
904 described or listed in this subdivision, except an anabolic  
905 steroid which is expressly intended for administration  
906 through implants to cattle or other nonhuman species and  
907 which has been approved by the Secretary of Health and Human  
908 Services for that administration;

909           (7) Dronabinol (synthetic) in sesame oil and  
910 encapsulated in a soft gelatin capsule in a United States  
911 Food and Drug Administration approved drug product;

912           (8) The department of health and senior services may  
913 except by rule any compound, mixture, or preparation  
914 containing any stimulant or depressant substance listed in  
915 subdivisions (1) and (2) of this subsection from the  
916 application of all or any part of sections 195.010 to  
917 195.320 if the compound, mixture, or preparation contains  
918 one or more active medicinal ingredients not having a  
919 stimulant or depressant effect on the central nervous  
920 system, and if the admixtures are included therein in  
921 combinations, quantity, proportion, or concentration that  
922 vitiate the potential for abuse of the substances which have  
923 a stimulant or depressant effect on the central nervous  
924 system.

925           7. The department of health and senior services shall  
926 place a substance in Schedule IV if it finds that:

927           (1) The substance has a low potential for abuse  
928 relative to substances in Schedule III;

929           (2) The substance has currently accepted medical use  
930 in treatment in the United States; and

931           (3) Abuse of the substance may lead to limited  
932 physical dependence or psychological dependence relative to  
933 the substances in Schedule III.

934           8. The controlled substances listed in this subsection  
935 are included in Schedule IV:

936           (1) Any material, compound, mixture, or preparation  
937 containing any of the following narcotic drugs or their  
938 salts calculated as the free anhydrous base or alkaloid, in  
939 limited quantities as set forth below:

940           (a) Not more than one milligram of difenoxin and not  
941 less than twenty-five micrograms of atropine sulfate per  
942 dosage unit;

943           (b) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-  
944 diphenyl-3-methyl-2-propionoxybutane);

945           (c) 2-[(dimethylamino)methyl]-1-(3-  
946 methoxyphenyl)cyclohexanol, its salts, optical and geometric  
947 isomers, and salts of these isomers (including tramadol);

948           (d) Any of the following limited quantities of  
949 narcotic drugs or their salts, which shall include one or  
950 more nonnarcotic active medicinal ingredients in sufficient  
951 proportion to confer upon the compound, mixture or  
952 preparation valuable medicinal qualities other than those  
953 possessed by the narcotic drug alone:

954           a. Not more than two hundred milligrams of codeine per  
955 one hundred milliliters or per one hundred grams;

956           b. Not more than one hundred milligrams of  
957 dihydrocodeine per one hundred milliliters or per one  
958 hundred grams;

959           c. Not more than one hundred milligrams of  
960 ethylmorphine per one hundred milliliters or per one hundred  
961 grams;

962           (2) Any material, compound, mixture or preparation  
963 containing any quantity of the following substances,  
964 including their salts, isomers, and salts of isomers

965 whenever the existence of those salts, isomers, and salts of  
966 isomers is possible within the specific chemical designation:

- 967 (a) Alfaxalone;
- 968 (b) Alprazolam;
- 969 (c) Barbitol;
- 970 (d) Bromazepam;
- 971 (e) Camazepam;
- 972 (f) Carisoprodol;
- 973 (g) Chloral betaine;
- 974 (h) Chloral hydrate;
- 975 (i) Chlordiazepoxide;
- 976 (j) Clobazam;
- 977 (k) Clonazepam;
- 978 (l) Clorazepate;
- 979 (m) Clotiazepam;
- 980 (n) Cloxazolam;
- 981 (o) Delorazepam;
- 982 (p) Diazepam;
- 983 (q) Dichloralphenazone;
- 984 (r) Estazolam;
- 985 (s) Ethchlorvynol;
- 986 (t) Ethinamate;
- 987 (u) Ethyl loflazepate;
- 988 (v) Fludiazepam;
- 989 (w) Flunitrazepam;
- 990 (x) Flurazepam;
- 991 (y) Fospropofol;
- 992 (z) Halazepam;
- 993 (aa) Haloxazolam;
- 994 (bb) Ketazolam;
- 995 (cc) Loprazolam;
- 996 (dd) Lorazepam;



997 (ee) Lormetazepam;  
998 (ff) Mebutamate;  
999 (gg) Medazepam;  
1000 (hh) Meprobamate;  
1001 (ii) Methohexital;  
1002 (jj) Methylphenobarbital (mephobarbital);  
1003 (kk) Midazolam;  
1004 (ll) **Mifepristone**;  
1005 (mm) Nimetazepam;  
1006 [(mm)] (nn) Nitrazepam;  
1007 [(nn)] (oo) Nordiazepam;  
1008 [(oo)] (pp) Oxazepam;  
1009 [(pp)] (qq) Oxazolam;  
1010 [(qq)] (rr) Paraldehyde;  
1011 [(rr)] (ss) Petrichloral;  
1012 [(ss)] (tt) Phenobarbital;  
1013 [(tt)] (uu) Pinazepam;  
1014 [(uu)] (vv) Prazepam;  
1015 [(vv)] (ww) Quazepam;  
1016 [(ww)] (xx) Suvorexant;  
1017 [(xx)] (yy) Temazepam;  
1018 [(yy)] (zz) Tetrazepam;  
1019 [(zz)] (aaa) Triazolam;  
1020 [(aaa)] (bbb) Zaleplon;  
1021 [(bbb)] (ccc) Zolpidem;  
1022 [(ccc)] (ddd) Zopiclone;  
1023 (3) Any material, compound, mixture, or preparation  
1024 which contains any quantity of the following substance  
1025 including its salts, isomers and salts of isomers whenever  
1026 the existence of such salts, isomers and salts of isomers is  
1027 possible: fenfluramine;

1028           (4) Any material, compound, mixture, or preparation  
1029 which contains any quantity of the following substances,  
1030 including its salts, isomers, and salts of isomers, whenever  
1031 the existence of such salts, isomers, and salts of isomers  
1032 is possible: Lorcaserin;

1033           (5) Any material, compound, mixture or preparation  
1034 containing any quantity of the following substances having a  
1035 stimulant effect on the central nervous system, including  
1036 their salts, isomers and salts of isomers:

1037           (a) Cathine ((+)-norpseudoephedrine);

1038           (b) Diethylpropion;

1039           (c) Fencamfamin;

1040           (d) Fenproporex;

1041           (e) Mazindol;

1042           (f) Mefenorex;

1043           (g) Modafinil;

1044           (h) Pemoline, including organometallic complexes and  
1045 chelates thereof;

1046           (i) Phentermine;

1047           (j) Pipradrol;

1048           (k) Sibutramine;

1049           (l) SPA ((-)-1-dimethylamino-1,2-diphenylethane);

1050           (6) Any material, compound, mixture or preparation  
1051 containing any quantity of the following substance,  
1052 including its salts:

1053           (a) Butorphanol (including its optical isomers);

1054           (b) Eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-  
1055 2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1 H-  
1056 imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid)  
1057 (including its optical isomers) and its salts, isomers, and  
1058 salts of isomers;

1059           (c) Pentazocine;

(7) Ephedrine, its salts, optical isomers and salts of optical isomers, when the substance is the only active medicinal ingredient;

(8) The department of health and senior services may except by rule any compound, mixture, or preparation containing any depressant substance listed in subdivision (1) of this subsection from the application of all or any part of sections 195.010 to 195.320 and sections 579.015 to 579.086 if the compound, mixture, or preparation contains one or more active medicinal ingredients not having a depressant effect on the central nervous system, and if the admixtures are included therein in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances which have a depressant effect on the central nervous system.

9. The department of health and senior services shall place a substance in Schedule V if it finds that:

(1) The substance has low potential for abuse relative to the controlled substances listed in Schedule IV;

(2) The substance has currently accepted medical use in treatment in the United States; and

(3) The substance has limited physical dependence or psychological dependence liability relative to the controlled substances listed in Schedule IV.

10. The controlled substances listed in this subsection are included in Schedule V:

(1) Any compound, mixture or preparation containing any of the following narcotic drugs or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below, which also contains one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture

1092 or preparation valuable medicinal qualities other than those  
1093 possessed by the narcotic drug alone:

1094 (a) Not more than two and five-tenths milligrams of  
1095 diphenoxylate and not less than twenty-five micrograms of  
1096 atropine sulfate per dosage unit;

1097 (b) Not more than one hundred milligrams of opium per  
1098 one hundred milliliters or per one hundred grams;

1099 (c) Not more than five-tenths milligram of difenoxin  
1100 and not less than twenty-five micrograms of atropine sulfate  
1101 per dosage unit;

1102 (2) Any material, compound, mixture or preparation  
1103 which contains any quantity of the following substance  
1104 having a stimulant effect on the central nervous system  
1105 including its salts, isomers and salts of isomers:  
1106 pyrovalerone;

1107 (3) Any compound, mixture, or preparation containing  
1108 any detectable quantity of pseudoephedrine or its salts or  
1109 optical isomers, or salts of optical isomers or any  
1110 compound, mixture, or preparation containing any detectable  
1111 quantity of ephedrine or its salts or optical isomers, or  
1112 salts of optical isomers;

1113 (4) Unless specifically exempted or excluded or unless  
1114 listed in another schedule, any material, compound, mixture,  
1115 or preparation which contains any quantity of the following  
1116 substances having a depressant effect on the central nervous  
1117 system, including its salts:

1118 (a) Brivaracetam ((2S)-2-[(4R)-2-oxo-4-  
1119 propylpyrrolidin-1-yl]butanamide) (also referred to as BRV;  
1120 UCB-34714; Briviact);

1121 (b) Ezogabine [N-[2-amino-4(4-fluorobenzylamino)-  
1122 phenyl]-carbamic acid ethyl ester];

1123 (c) Lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy-  
1124 propionamide];

1125 (d) Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic  
1126 acid];

1127 (5) Any drug product in finished dosage formulation  
1128 that has been approved by the U.S. Food and Drug  
1129 Administration that contains cannabidiol (2-[1R-3-methyl-6R-  
1130 (1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-  
1131 benzenediol) derived from cannabis and no more than 0.1  
1132 percent (w/w) residual tetrahydro cannabinoids.

1133 11. If any compound, mixture, or preparation as  
1134 specified in subdivision (3) of subsection 10 of this  
1135 section is dispensed, sold, or distributed in a pharmacy  
1136 without a prescription:

1137 (1) All packages of any compound, mixture, or  
1138 preparation containing any detectable quantity of  
1139 pseudoephedrine, its salts or optical isomers, or salts of  
1140 optical isomers or ephedrine, its salts or optical isomers,  
1141 or salts of optical isomers, shall be offered for sale only  
1142 from behind a pharmacy counter where the public is not  
1143 permitted, and only by a registered pharmacist or registered  
1144 pharmacy technician; and

1145 (2) Any person purchasing, receiving or otherwise  
1146 acquiring any compound, mixture, or preparation containing  
1147 any detectable quantity of pseudoephedrine, its salts or  
1148 optical isomers, or salts of optical isomers or ephedrine,  
1149 its salts or optical isomers, or salts of optical isomers  
1150 shall be at least eighteen years of age; and

1151 (3) The pharmacist, intern pharmacist, or registered  
1152 pharmacy technician shall require any person, prior to such  
1153 person's purchasing, receiving or otherwise acquiring such  
1154 compound, mixture, or preparation to furnish suitable photo

1155 identification that is issued by a state or the federal  
1156 government or a document that, with respect to  
1157 identification, is considered acceptable and showing the  
1158 date of birth of the person;

1159 (4) The seller shall deliver the product directly into  
1160 the custody of the purchaser.

1161 12. Pharmacists, intern pharmacists, and registered  
1162 pharmacy technicians shall implement and maintain an  
1163 electronic log of each transaction. Such log shall include  
1164 the following information:

1165 (1) The name, address, and signature of the purchaser;

1166 (2) The amount of the compound, mixture, or  
1167 preparation purchased;

1168 (3) The date and time of each purchase; and

1169 (4) The name or initials of the pharmacist, intern  
1170 pharmacist, or registered pharmacy technician who dispensed  
1171 the compound, mixture, or preparation to the purchaser.

1172 13. Each pharmacy shall submit information regarding  
1173 sales of any compound, mixture, or preparation as specified  
1174 in subdivision (3) of subsection 10 of this section in  
1175 accordance with transmission methods and frequency  
1176 established by the department by regulation;

1177 14. No person shall dispense, sell, purchase, receive,  
1178 or otherwise acquire quantities greater than those specified  
1179 in this chapter.

1180 15. All persons who dispense or offer for sale  
1181 pseudoephedrine and ephedrine products in a pharmacy shall  
1182 ensure that all such products are located only behind a  
1183 pharmacy counter where the public is not permitted.

1184 16. The penalties for a knowing or reckless violation  
1185 of the provisions of subsections 11 to 15 of this section  
1186 are found in section 579.060.

1187           17. The scheduling of substances specified in  
1188 subdivision (3) of subsection 10 of this section and  
1189 subsections 11, 12, 14, and 15 of this section shall not  
1190 apply to any compounds, mixtures, or preparations that are  
1191 in liquid or liquid-filled gel capsule form or to any  
1192 compound, mixture, or preparation specified in subdivision  
1193 (3) of subsection 10 of this section which must be  
1194 dispensed, sold, or distributed in a pharmacy pursuant to a  
1195 prescription.

1196           18. The manufacturer of a drug product or another  
1197 interested party may apply with the department of health and  
1198 senior services for an exemption from this section. The  
1199 department of health and senior services may grant an  
1200 exemption by rule from this section if the department finds  
1201 the drug product is not used in the illegal manufacture of  
1202 methamphetamine or other controlled or dangerous  
1203 substances. The department of health and senior services  
1204 shall rely on reports from law enforcement and law  
1205 enforcement evidentiary laboratories in determining if the  
1206 proposed product can be used to manufacture illicit  
1207 controlled substances.

1208           19. The department of health and senior services shall  
1209 revise and republish the schedules annually.

1210           20. The department of health and senior services shall  
1211 promulgate rules under chapter 536 regarding the security  
1212 and storage of Schedule V controlled substances, as  
1213 described in subdivision (3) of subsection 10 of this  
1214 section, for distributors as registered by the department of  
1215 health and senior services.

1216           21. Logs of transactions required to be kept and  
1217 maintained by this section and section 195.417 shall create  
1218 a rebuttable presumption that the person whose name appears

1219 in the logs is the person whose transactions are recorded in  
1220 the logs.

579.018. 1. A person commits the offense of coerced  
2 criminal abortion by means of fraud if the person knowingly  
3 and intentionally engages in the use of an abortion-inducing  
4 drug on a pregnant woman without her knowledge or consent  
5 with the intent to cause an abortion.

6 2. The offense of coerced criminal abortion by means  
7 of fraud is a class B felony.

8 3. A prosecution of a person under this section shall  
9 not be a defense against a prosecution under any other  
10 provision of law, including murder, if the person commits  
11 the offense of coerced criminal abortion by means of fraud  
12 and the use of an abortion-inducing drug results in the  
13 death or serious bodily injury of the pregnant woman.

✓